anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Corneal Ulcers: The recommended dosage regimen for the treatment of corneal ulcers is two drops into the affected eye every 15 minutes for the first six hours and then two drops into the affected eye every 30 minutes for the remainder of the first day. On the second day, instill two drops in the affected eye hourly. On the third through the fourteenth day, place two drops in the affected eye every four hours. Treatment may be continued after 14 days if corneal re-epithelialization has not occurred.

Bacterial Conjunctivitis: The recommended dosage regimen for the treatment of bacterial conjunctivitis is one or two drops instilled into the conjunctival sac(s) every two hours while awake for two days and one or two drops every four hours while awake for the next five days.

How Supplied: As a sterile ophthalmic solution, in a plastic dispenser:

5 mL NDC 63187-150

STORAGE: Store at 25°C (77°F); excursions permitted to15 - 30°C (59 - 86°F) [See USP controlled room temperature]. Protect from light. Retain in carton until contents are used.
The present invention relates to a compositions for and methods of cancer treatment in which compounds of Formula I or Formula II. In some aspects, the treatment of B-cell Lymphoma or other hematopoietic cancers is encompassed. In other aspects, the invention provides methods for treating particular types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more compounds of Formula I or Formula II. Combination therapy with, for example, a class of therapeutics known as 26S proteasome inhibitors, for example, Bortezomib, are also included. In another aspect the present invention relates to autoimmune treatment with compounds of Formula I or Formula II. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.
Participants will receive single dose of GDC-0973 2 mg IV infusion in first intervention period followed by single dose of GDC-0973 20 mg oral capsules (four 5-mg capsules) in second intervention period. The washout period between each period will be a minimum of 10 days.
Participants who have PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 3 and showing no symptom of nausea and/or vomiting during the three control visits. Control visits are performed a month apart.
People with multiple sclerosis (MS) often experience dizziness, caused by problems in how their brain processes balance signals. This dizziness can lead to difficulties keeping their eyes focused on a target while moving their head, known as gaze instability. This makes activities like walking or driving challenging and dangerous. Vestibular physical therapy, including gaze stabilization exercises, can help. The team developed StableEyes, a technology that improves gaze stability using a gradual approach to these exercises. In the studies, StableEyes significantly enhanced gaze stability in people with balance issues. Preliminary research in people with MS shows promising results, suggesting that tailored gaze stability exercises can further improve their vision stability. This method targets the vestibulo-ocular reflex (VOR), a critical reflex for maintaining clear vision during head movements. Improved VOR function can reduce dizziness and improve the quality of life for people with MS.
A dry stable composition is provided. The composition comprises one or more viable microorganisms, at least 50% by weight of one or more hydrolyzed proteins and less than 10% by weight of one or more sugars selected from the group consisting of monosaccharides, disaccharides and combinations thereof, each weight percentage based on the total weight of the dry composition. Preferably, the composition comprises no monosaccharide or disaccharide. The composition may further comprise one or more oligosaccharides, one or more polysaccharides, one or more carboxylic acid salts, or a combination thereof. The composition may have viability of at least 1 X 10 10  CFU/g, and a viability loss of less than 1 log unit/g after 84 days at a temperature of 40°C and a relative humidity of 33%. Also provided are methods for preparing the dry stable composition.
URINARY INCONTINENCE IN CHILDREN. Urinary incontinence in children and adolescents is most often of functional origin. Questioning and clinical examination with a bladder diary should look for underlying urological or neurological causes. The type of incontinence, daytime or nocturnal, must be specified to adapt treatments. Renal and bladder ultrasound is recommended, and urodynamic studies are not routinely used. Lifestyle advice and bowel management are prerequisites for treatment. Depending on the type of symptoms, drug treatment, pelvic floor treatment, behavioral measures or stimulation of the posterior tibial nerve can be proposed. The evolution can sometimes be slow with a significant impact on quality of life, and neurocognitive aspects need to be considered.
Terminal differentiation is associated with repression in the expression of the P2P subset of hnRNP proteins. The 5173 base pair P2P cDNA was cloned and characterized. The cDNA contains a 4214 base pair open reading frame. Probes to the P2P cDNA detect a single 8 kb mRNA in multiple murine tissues, in proliferating murine 3T3T cells but not in terminally differentiated 3T3T adipocytes. Evidence that the P2P cDNA can encode proteins with domains for hnRNP association was established by showing that the C130 monoclonal antibody, produced against a fusion protein derived from the P2P cDNA, selectively detects native P2P hnRNP proteins. In addition, it was shown that P2P antisense oligonucleotides selectively repressed 30-40 kDa P2P expression. Since terminal differentiation is also associated with modulation in Rb1 function, assays were performed which demonstrated that P2P cDNA products interact with Rb1. Evidence that the P2P cDNA encodes a protein domain that binds Rb1 was established using a GST-P2P fusion protein to selectively precipitate Rb1. Data also show that this binding is competed by the adenovirus E1a protein, indicating that binding occurs through the “pocket” domain of Rb1. These results establish that the P2P cDNA encodes protein domains involved in both hnRNP association and Rb1 binding and complement recent reports that localize Rb1 to sites of RNA processing in the nucleus. The interaction of P2P cDNA products and Rb1 may therefore serve to modulate cell proliferation and/or other biological functions associated with tumor suppression by an RNA processing mechanism.
Patients with unresectable and/or metastatic cutaneous melanoma. Patients must not have received prior systemic anticancer therapy for unresectable or metastatic melanoma. Prior adjuvant and/or neoadjuvant PD-\[L\]1 treatments are allowed if there is at least 6 months between the last dose and date of recurrence.
PURPOSE:To provide an antiarteriosclerotic agent, by culturing diatoms in a culture liquid containing soil percolation liquid, extracting oily substance from the tissue of the diatom, separating a specific lipid from the substance, and using the lipid as an active component. CONSTITUTION:Diatom is cultured in a culture liquid consisting of a soil percolation liquid, preferably a liquid obtained by adding 0.1-1% of compost percolation liquid to the base liquid having the composition of table I . The aeration is stopped after the cultivation, and the precipitated diatoms are collected and separated from the culture liquid, dried with hot air, ground, and extracted with a solvent incompatible with water (e.g. kerosine, petroleum ether, etc.) to obtain an oily substance. A lipid containing omega-3-eicosapentaenoic acid as a main constituent fatty acid is separated from the oily substance by column chromatography, etc. The lipid is used as an active component of the objective antiarteriosclerotic agent. EFFECT:The easily culturable diatom can be used as the raw material, and the agent can be supplied stably at a low cost.
FIELD: medicine. SUBSTANCE: method involves applying chemotherapy courses according to schedule. 5-fluoruracyl is intravenously administered at a dose of 1000 mg/m 2  daily as continuous 120 h long infusion from the first to fifth day. Cyclophosphane is intravenously administered at the first and the eighth day at a dose of 600 mg/m 2  and metatrexate at a dose of 40 mg/m 2  as single doses. Two weeks later, when the second chemotherapy course is over, distant gamma therapy is applied to injured gland and regional lymph circulation zone according to radical program. The therapy course being effective and process operability being considered to be the case, additional radical mastectomy is done four weeks later after accomplishing radiation therapy course. 1-2 chemotherapy courses are applied in the postoperative period. EFFECT: enhanced effectiveness of treatment.
PURPOSE: The objective was to compare pain and related psychological factors during the preoperative and acute postoperative period between male and female patients, who underwent non mesh primary unilateral inguinal hernia repair.
METHODS: After ethics approval, informed consent was obtained, and data were collected. Male and female participants were compared by manually matching one-to-one on 10 variables. Descriptive statistics (mean ± standard deviation and frequency) as well as numerical rating scales from 0 to 10 were used. Comparison tests were performed using Chi-square or Fisher's Exact test for categorical data and independent samples t-test or non-parametric equivalent tests for numerical scores. p < 0.05 is reported as statistically significant. To control type I error, Bonferroni correction was used.
RESULTS: 72 participants with 36 matched pairs were included. Sex differences were found for operation length (p = .006), side of operation (p = .002), and hernia type (p = .013). Significant differences between the sexes were not found at the preoperative or postoperative time for resilience, pain interference or pain severity related measures, postoperative hernia pain incidence, pain catastrophizing, depression and anxiety symptoms, or return to normal activities.
CONCLUSION: When controlling for known confounders and using a conservative Type I error rate, pain and related factors between the sexes did not differ significantly.
The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like.
The invention relates to a dressing umbilicus traditional Chinese medicine for treating limb swelling and pain caused by fracture. The dressing umbilicus traditional Chinese medicine is prepared from peach kernels, raw rhubarb, raw gardenia jasminoides ellis, semen strychni, red paeony roots, rhizoma drynariae, cassia twigs, angelica sinensis, pseudo-ginsengs, safflower carthamus, borneol and camphor. The dressing umbilicus traditional Chinese medicine is characterized in that the raw materials are as follows in parts by weight: 18-22 parts of the paeony roots, 28-32 parts of rhizoma drynariae, 18-22 parts of cassia twigs, 28-32 parts of angelica sinensis, 28-32 parts of pseudo-ginsengs, 12-16 parts of safflower carthamus, 8-12 parts of borneol and 6-10 parts of camphor. A proper amount of medicine powder is taken, is wetted with a 0.9% sodium chloride solution, and then is put into an umbilicus therapy bag. The dressing umbilicus traditional Chinese medicine is dressed on an umbilicus of a patient twice a day and is dressed for 1 hour each time; one treatment course lasts for seven days. The dressing umbilicus traditional Chinese medicine is reasonable in composition, low in cost, rapid in effect, safe to use, and simple and feasible; the treatment effect is definite; and after the dressing umbilicus traditional Chinese medicine is used, the detumescence speed of limbs is high and the pain of the injured limb can be effectively relieved.
The present invention provides novel inhibitors of the enzyme D- amino acid oxidase. The compounds of the invention are useful for treating or preventing diseases and/ or conditions, wherein modulation of D- serine levels, and/or its oxidative products, is effective in ameliorating symptoms. The invention further provides methods of enhancing learning, memory and/or cognition. For example, the invention provides methods for treating or preventing loss of memory and/or cognition associated with neurodegenerative diseases, such as Alzheimer's disease. The invention further provides methods for preventing loss of neuronal function characteristic of neurodegenerative diseases. In addition, methods are provided for the treatment or prevention of neuropsychiatry diseases (e.g., schizophrenia) and for the treatment or prevention of pain and ataxia.
In the lateral decubitus position. Right block will be performed; the patient will then repositioned for the left block. An ultrasound device with a convex probe (5-8 MHz) will be placed in the mid-axillary line just above the iliac crest. Then, scan dorsally to keep the transverse orientation until seeing the aponeurosis of the transverses abdominus muscle and by following this aponeurosis, QL muscle will be visualized with its attachment to the lateral edge of the transverse process of the L2 vertebral body and visualize the thoracolumbar fascia at the lateral edge of the QL muscle. A spinal needle (20G) will be inserted in-plane from the anterior to posterior direction, and the tip of the needle will be advanced anterior to the QL muscle. The target site for injection is the plane between the quadratus lumborum and psoas major muscles. This will be followed by injection of 0.25% bupivacaine 20 ml in each side.
INTRODUCTION: Diagnosis, outcomes, and costs of care associated with bowel dysfunction after proctectomy for cancer remain underexplored in population-based studies. The lack of administrative coding for bowel dysfunction or low anterior resection syndrome has historically limited secondary data set outcomes analysis. The purpose of this study was to identify a bowel dysfunction phenotype in administrative claims data and characterize its prevalence, predictive factors, and costs.
MATERIALS AND METHODS: Patients were identified with employer-sponsored commercial insurance (MarketScan research databases) undergoing proctectomy for cancer for a retrospective cohort study. Bowel dysfunction was defined as any patient with diagnostic codes for diarrhea, constipation, incontinence, pelvic floor diagnostic testing, or rehabilitative procedures that occurred in the 18 mo to follow surgery. We performed Poisson regression to identify statistically significant covariates of bowel dysfunction occurrence following low anterior resection. A secondary comparative analysis was also performed of total costs of healthcare utilization following gastrointestinal continuity.
RESULTS: 6426 proctectomy patients were identified, out of which 2131 had surgery for cancer. 847 patients undergoing proctectomy for cancer (39.7%) experienced bowel dysfunction during 18 mo of follow-up. The most common diagnoses were constipation (53.5%) and diarrhea (40.3%). Diagnostic procedures and rehabilitative procedures were performed in only 29.8% of those with symptoms. Neoadjuvant chemotherapy administration with radiation (incidence rate ratio = 1.23, 95% CI: 1.01-1.51) and without (incidence rate ratio = 1.20, 95% CI: 1.01-1.42) remained associated with postoperative bowel dysfunction when controlling for other factors. Chemoradiation therapy alone was not associated with bowel dysfunction. The median total follow-up costs with bowel dysfunction were $30,769 greater (P < 0.001).
CONCLUSIONS: More than one-third of patients have symptomatic bowel dysfunction within 18 mo after restored continuity, with multiagent chemotherapy being the strongest independent predictor. Bowel dysfunction is associated with more than twice healthcare costs postop.
BACKGROUND: The assessment of scar outcomes is important to both patient care and research focused on understanding the results of medical and surgical interventions. The Vancouver Scar Scale (VSS) and Patient and Observer Scar Assessment Scale (POSAS) are validated and simple instruments to assess scars. However, these subjective scales have shortcomings. The VSS fails to capture patient perception and has indeterminate validity and reliability. The POSAS captures patient perception, but the observer scale has been shown to have moderate amounts of interrater variability. Studies highlighting the ability of objective scar assessment tools to produce reliable and reproducible results are needed. In this study, the authors aimed to validate the use of the FibroMeter, ElastiMeter, and SkinColorCatch as objective adjuncts in the assessment of hypertrophic scar and keloid outcomes.
METHODS: In this prospective single-center study, scars were assessed using the VSS, the POSAS, and the objective study tools (FibroMeter, ElastiMeter, and SkinColorCatch). Correlations between the different methods of scar assessment were measured.
RESULTS: The FibroMeter and SkinColorCatch showed significant correlations with the VSS total and the observer POSAS total. The ElastiMeter showed significant correlations with both the patient and observer POSAS totals. Unexpected correlations between ElastiMeter measurements and the vascularity or pigmentation of scars indicate that scoring of these categories may be influenced by how severe the scar looks to the observer subjectively, underscoring the need for reliable objective scar assessment tools.
CONCLUSION: The results highlight the ability of the FibroMeter, ElastiMeter, and SkinColorCatch to assess scars, and demonstrate their potential in serving as important adjuncts to previously validated scar assessment scales.
The poor maintenance of eating behavior change is one of the main obstacles to minimizing weight regain after weight loss during diets for non-surgical care of obese or overweight patients. We start with a known informal explanation of interruption in eating behavior change during severe restriction and formalize it as a causal network involving psychological variables, which we extend with energetic variables governed by principles of thermodynamics. The three core phenomena of dietary behavior change, i.e., non-initiation, initiation followed by discontinuation and initiation followed by non-discontinuation, are expressed in terms of the value of the key variable representing mood or psychological energy, the fluctuation of which is the result of three causal relationships. Based on our experimental knowledge of the time evolution profile of the three causal input variables, we then proceed to a qualitative analysis of the resulting theory, i.e., we consider an over-approximation of it which, after discretization, can be expressed in the form of a finite integer-based model. Using Answer Set Programming, we show that our formal model faithfully reproduces the three phenomena and, under a certain assumption, is minimal. We generalize this result by providing all the minimal models reproducing these phenomena when the possible causal relationships exerted on mood are extended to all the other variables (not just those assumed in the informal explanation), with arbitrary causality signs. Finally, by a direct analytical resolution of an under-approximation of our theory, obtained by assuming linear causalities, as a system of linear ODEs, we find exactly the same minimal models, proving that they are also equal to the actual minimal models of our theory since these are framed below and above by the models of the under-approximation and the over-approximation. We determine which parameters need to be person-specific and which can be considered invariant, i.e., we explain inter-individual variability. Our approach could pave the way for universally accepted theories in the field of behavior change and, more broadly, in other areas of psychology.
AIM: Some patients with inflammatory bowel disease (IBD) require subtotal colectomy (STC) with ileostomy. The recent literature reports a significant number of patients who do not undergo subsequent surgery and are resigned to living with a definitive stoma. The aim of this work was to analyse the rate of definitive stoma and the cumulative incidence of secondary reconstructive surgery after STC for IBD in a large national cohort study.
METHOD: A national retrospective study (2013-2021) was conducted on prospectively collected data from the French Medical Information System Database (PMSI). All patients undergoing STC in France were included. The association between definitive stoma and potential risk factors was studied using univariate and multivariate analyses.
RESULTS: A total of 1860 patients were included (age 45 ± 9 years; median follow-up 30 months). Of these, 77% (n = 1442) presented with ulcerative colitis. Mortality and morbidity at 90 days after STC were 5% (n = 100) and 47% (n = 868), respectively. Reconstructive surgery was identified in 1255 patients (67%) at a mean interval of 7 months from STC. Seveny-four per cent (n = 932) underwent a completion proctectomy with ileal pouch anal anastomosis and 26% (n = 323) an ileorectal anastomosis. Six hundred and five (33%) patients with a definitive stoma had an abdominoperineal resection (n = 114; 19%) or did not have any further surgical procedure (n = 491; 81%). Independent risk factors for definitive stoma identified in multivariate analysis were older age, Crohn's disease, colorectal neoplasia, postoperative complication after STC, laparotomy and a low-volume hospital.
CONCLUSION: We found that 33% of patients undergoing STC with ileostomy for IBD had definitive stoma. Modifiable risk factors for definitive stoma were laparotomy and a low-volume hospital.
This study is designed to investigate the epidemiologic, genetic, laboratory and clinical characterization of individuals with coronary artery disease. The study group will consist of consecutive patients who are undergoing coronary angiography for suspected coronary artery disease. The diagnosis of coronary artery disease will be confirmed by coronary angiography performed with the Judkins technique using a quantitative coronary angiographic system. Coronary artery disease will be considered to be present if there is a diameter stenosis of at least 50% in at least one of the three major epicardial coronary arteries. The number of diseased vessels will be determined and a classification of 1-, 2-, and 3-vessel disease will be used. Coronary artery segments will be defined according to the Coronary Artery Surgery Study classification. Blood samples from vein and coronary artery will be collected. We will study coronary arteriovenous difference of various markers. Urinary samples will be obtained the day of coronary angiography. We will explore the environmental (including family history, life style, diet, physical activity, neuropsychological functioning，plasma levels of oxidative stress factors, angiogenic factors, and inflammatory markers, etc.) and genetic (including oxidative stress factors and inflammatory factors, etc.) risk factors. We will study the association between various environmental risk factors with the clinical characterization and correlation between the genetic polymorphisms and the presence of coronary artery disease.